TGFB1 and esophageal squamous cell carcinoma: SB505124 is another TβR I inhibitor that inhibits the activation of fibroblasts induced by TGF-β, thereby preventing esophageal squamous cell carcinoma- (ESCC-) induced neoangiogenesis [171].